A Phase 1 Dose Escalation Study of Combination Therapy With Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Pilaralisib (Primary) ; Pimasertib (Primary)
- Indications Breast cancer; Colorectal cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 22 Aug 2012 Actual end date (July 2012) added as reported by ClinicalTrials.gov.
- 26 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.